Drug intelligence / Profile preview

6-[(1-naphthylmethyl)sulfanyl]-9H-purine

Development stage: Preclinical
Modality: Small Molecules

Overview

6-[(1-naphthylmethyl)sulfanyl]-9H-purine (NMMP) is a small molecule derivative of 6-mercaptopurine (6-MP) that has demonstrated anti-tumor activities. It inhibits the proliferation of various human cancer cell lines, including hepatocellular carcinoma (HepG2) cells, by inducing G2/M phase cell cycle arrest and mitochondria-dependent apoptosis. Its mechanism involves reducing levels of cyclin-dependent kinase 4 (CDK4) and cyclins B1/D1, and increasing the expression of cleaved caspase-9 and caspase-3, as well as the Bax/Bcl-2 protein ratio. These actions suggest its potential therapeutic value for cancer treatment.

Targets

CDK4 (Cyclin-dependent kinase 4)BAX (Apoptosis regulator BAX)CASP3 (Caspase-3)CASP9 (Caspase-9)CCNB1 (Cyclin B1)CCND1 (Cyclin D1)

Beyond the preview

Go deeper on 6-[(1-naphthylmethyl)sulfanyl]-9H-purine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 6-[(1-naphthylmethyl)sulfanyl]-9H-purine.

Explore the full profile